Researchers have identified how CBD interacts with cannabinoid receptors to mitigate the negative effects of THC, the psychoactive component of cannabis.

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Announcing a new article publication for BIO Integration journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in China in December 2019, rapidly spread worldwide, ...

Innovative designs of GPCRs with enhanced signaling and stability offer new insights for drug discovery and synthetic biology ...

University of Mississippi researchers have discovered how a compound found in cannabis might be used to mitigate the negative ...

A new study on brain activity found that heavy cannabis use is linked to reduced activity in memory-related regions, while ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...

A team from UNIGE, the Max Planck Institute for Molecular Physiology in Dortmund, and Heinrich Heine University in Düsseldorf ...